Adaptive Biotechnologies COO Executes Scheduled Share Sale via 10b5-1 Plan

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (NASDAQ: ADPT), has completed a series of share dispositions between April 9 and April 13, 2026. The transactions were disclosed in a recent SEC Form 4 filing. The sales were executed under a Rule 10b5-1 trading plan, which allows corporate insiders to sell a predetermined number of shares at set times to avoid accusations of insider trading. Because these sales were scheduled months in advance, they are generally viewed by analysts as routine liquidity events rather than a reflection of the executive's current outlook on the company's valuation. According to the filing, Rubinstein sold 44,166 common shares at a weighted average price of $13.26 per share, totaling approximately $758,000. These shares were acquired through the exercise of options. Despite the sale, Rubinstein maintains a substantial economic stake in the company, holding 421,174 shares directly and 192,936 unexercised options. For investors, the focus remains on Adaptive Biotechnologies' operational milestones rather than insider liquidation. Key performance indicators, such as the growth of clonoSEQ volumes and the expansion of biopharma collaboration revenue, remain the primary metrics that will influence the company's path toward profitability.